Although the two small, underpowered, retrospective and non-randomised studies [2,22] show that FcgR polymorphisms are associated with anti-tumour efficacy of trastuzumab, the well powered analysis of Hurvitz et al. [23] indicates that FcgR polymorphisms are not useful as predictive biomarkers of trastuzumab response in HER2-positive breast cancer, particularly in early stage disease. The gene discussed is FCGR2A; the disease is neoplasm.